Last checked at 
LONDON (Alliance News) - ValiRx PLC Friday said its joint venture with Tangent Reprofiling Ltd, ValiSeek Ltd, has received a US patent for VAL401 for the treatment of adenocarcinoma.
"This further US patent has been allowed at an opportune moment as we progress through our clinical trial preparations. At such a late stage in our preparations of the Clinical Trial for VAL401 the fact that the compound is now in receipt of additional IP protection, adds value to shareholder funds and further endorses our joint venture," said Chief Executive Officer of ValiSeek Suzanne Dilly in a statement.
"This is a powerful confirmation of the science lieing behind VAL401 and I very much look forward to following VAL401 on its clinical trial pathway," Chief Executive Officer of ValiRx Satu Vainikka added.
Shares in ValiRx were up 2.5% at 9.99 pence Friday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.